

Serial No. 09/777,091

PATENT

REMARKS

In the Office action of September 10, 2003, Paper No. 22, claims 1-6,10-13,15,16,19-22,25-30,36, and 46-55 were pending with claims 7-9,14,17,18,23,24,31-35 and 42-45 having been withdrawn from consideration. Claims 1,2,4,5,10-12,15,16,19-22,25-30,36, and 46-55 are rejected. Claims 6 and 13 are objected to. In particular, claims 36 was rejected under 35 U.S.C. 112, first paragraph, because the Examiner decided that the best mode contemplated by the inventor has not been disclosed. Claims 2,11,19-22,25-30, and 46-54 were rejected under 35 U.S.C. 112, second paragraph, as being indefinite. Claims 19,28,36, and 48 are rejected under U.S.C. 102(b) as being anticipated by Boretos et al. Claims 19,28,36, and 48 are rejected under U.S.C. 102(b) as being anticipated by Reul. Claim 36 is rejected under U.S.C. 102(b) as being anticipated by Cox. Claims 36,50-54, and rejected under U.S.C. 102(e) as being anticipated by Bessler et al. Claims 1,2,4,5,12,36, and 50-54 are rejected under U.S.C. 102(e) as being anticipated by Moll et. al. Claims 20-22 and 49 are rejected under U.S.C. 103(a) as being unpatentable over Boretos et al. in view of Bessler. Claims 25-27 are rejected under U.S.C. 103(a) as being unpatentable over Boretos et al. in view of Cox. Claims 47 and 55 are rejected under 35 U.S.C. 103(a) as being unpatentable over Bessler in view of Cox. Claims 10,11,46,47, and 55 are rejected under 103(a) as being unpatentable over Moll et al. in view of Cox. Claims 15 and 16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Moll et al. in view of Bessler et al.

Claim Objections

With regard to point a of the Claim Objections from the Office Action of September 11, 2003, claims 4 and 5 are being amended such that

Serial No. 09/777,091

PATENT

they both depend from claim 1. With regard to point b, claim 36 is now withdrawn and thus, the objection will not be addressed. With regard to point c, claim 46, is being withdrawn although Applicants disagree that 'theraround' is an improper word. Point d is also rendered moot by the cancellation of claim 50. With regard to point e, the appropriate correction to claim 55 is made. Applicants' response to the Examiner's other points are found below.

Claim Rejections 35 USC § 112

**Examiner's Point 4:**

Claim 36 is being withdrawn by this response, making unnecessary to present Applicants' arguments regarding the merits of Point 4.

**Examiner's Point 6:**

Regarding points 6a-b, 'vascular valve' has been replaced with 'implantable valve' and 'free edge' has been replaced with 'inner edge' in claim 2, thereby correcting the respective antecedent problems. Regarding point 6c, Claim 11 is amended to properly depend on Claim 10. Points 6d-i are now moot as these claims are being withdrawn.

Claim Rejections 35 USC § 102

**Examiner's Points 8-11:**

Claims 19,28,36, 48, and 50-54 are being withdrawn from consideration.

**Examiners' Point 12:**

Serial No. 09/777,091

PATENT

Claim 1 stands rejected under 35 U.S.C. 102(e) based upon the assertion that it is anticipated by U.S. Patent No. 6,287,334 (Moll et al.). This rejection is respectfully traversed for the following reasons.

The legal standard for anticipation requires that the reference expressly or inherently teach each and every element of the claim. Where the Patent Office intends to rely upon inherent teachings of a reference, the features relied upon must necessarily be present in the reference. Mere possibilities will not suffice. Under the doctrine of inherency, if an element is not expressly disclosed in a prior art reference, the reference will still be deemed to anticipate a subsequent claim if the missing element "is necessarily present in the thing described in the reference, and that it would be so recognized by persons of ordinary skill." Cont'l Can Co. v. Monsanto Co., 948 F.2d 1264, 1268, 20 USPQ2d 1746, 1749 (Fed. Cir. 1991). "Inherent anticipation requires that the missing descriptive material is 'necessarily present,' not merely probably or possibly present, in the prior art." Trintec Indus., Inc. v. Top-U.S.A. Corp., 295 F.3d 1292, 1295, 63 USPQ2d 1597, 1599 (Fed. Cir. 2002) (quoting *In re Robertson*, 169 F.3d 743, 745, 49 USPQ2d 1949, 1950-51 (Fed. Cir. 1999)).

Claim 1 includes the feature "the outer edge of each one of the plurality of leaflets attached along one side element of said plurality of side elements and thereby adapted to engage the wall of the bodily passage". Moll et al. does not expressly teach anything concerning this feature, and therefore it is assumed that the Office Action's rejection was made based upon the position that this feature is inherent in the Moll et al. teachings. However, in its specification, Moll et al. only teaches that the "[b]lood flow stoppage elements 6, having the form of flexible hollow cones, are each supported on a substantially triangular frame section 8 of a support 10...". Similarly, in its Figures, Moll et al. lacks any illustration of this claimed feature (see in particular Figure 1). Accordingly, there is no express or inherent teaching of each and every element of claim 1 in the Moll et al. patent.

Serial No. 09/777,091

PATENT

Although Applicants argue that Moll et al. clearly does not include the features necessary for it to anticipate Applicants' claim 1, Applicants have decided to add an additional limitation to better place the claim in condition for allowance. The new language includes the following limitation:

"each of said leaflets thereby forming a curved structure for trapping fluid between the leaflets and the inner wall of the bodily passage in response to fluid flow in said second direction so as to cause said inner edges of said leaflets to engage one another sufficiently to restrict fluid flow in said second direction."

Moll only teaches trapping retrograde-flowing fluid within a pocket, and such, blood is not trapped against the wall by any part of valve as required by Applicants' amended claim 1. This is an important difference that materially affects the ability of the valve to function properly. Withdrawal of the rejection of claim 1 (and its dependent claims 2, 4, 5 and 12) under 35 U.S.C. 102(e) over Moll et al. is therefore solicited..

Claim Rejections 35 USC § 103

**Examiner's Points 14 and 15:**

Claims 20-22, 25-27, and 49 are now cancelled from this application so there is no need to address the Examiner's reasons for rejection at this time.

**Examiner's Point 16:**

Claim 55 (and now-cancelled claim 47) stands rejected under 35 USC 103(a) based upon the assertion that it is unpatentable over U.S. Patent No. 5,855,601 (Bessler et al.) in view of U.S. Patent No. 5,713,950 (Cox). This rejection is respectfully traversed because even assuming these

Serial No. 09/777,091

PATENT

two references are combinable as asserted in the Office Action, they clearly fail to teach or suggest elements of the claim.

In support of this rejection, the Office Action takes the position that "Bessler et al. disclose the invention as claimed except for disclosing the covering or plurality of leaflets as comprising small intestinal submucosa". This position is not correct. Claim 55 includes the feature of "the outer edge of each one of the plurality of leaflets attached along one side element of said plurality of side elements and thereby adapted to engage the wall of the bodily passage". This feature is not taught in Bessler et al., which only teaches that "[t]he cuff portion is attached to the stent by sutures 38". See Col. 5, lines 41-42 and Figures showing single-point attachment of the cuff to straight sections 33 by sutures 38. Nor is there any motivation provided within Bessler et al. to modify its device to meet the claimed feature. To the contrary, Bessler et al. describes their device to be functional in the fashion they desire, as shown.

Looking to the Cox reference, there are absolutely no teachings to supplement the above-noted shortcomings of Bessler et al. In fact, Cox only teaches the use of a stent in conjunction with an otherwise implanted valve, wherein the stent "could be secured within the aortic wall 250, outside of the SIS segment 200. This type of stent, if used, would contain [sic] projections which extend in an inward radial direction, toward the central axis of the aorta. These projections, which would be positioned at the midpoints between the three attachment points at the outlet end, would prevent any flattening of the cusp regions 222 against the interior of aortic wall 250." See Col. 24, lines 3-17. Accordingly, Cox does not teach any attachment of the valve material to the stent as claimed, and thus cannot in any way supplement the teachings of Bessler et al. in a manner to render the present claims obvious.

For the above reasons, the rejection of claim 55 under 35 U.S.C. 103(a) over the combination of Bessler et al. and Cox is overcome, and its withdrawal is solicited.

Serial No. 09/777,091

PATENT

## Examiner's Point 17:

Claim 55 stands rejected under 35 USC 103(a) based upon the assertion that it is unpatentable over U.S. Patent No. 6,287,334 (Moll et al.) in view of U.S. Patent No. 5,713,950 (Cox). This rejection is also respectfully traversed, because even assuming these two references are combinable as asserted in the Office Action, they clearly fail to teach or suggest elements of the claim.

In support of this rejection, the Office Action takes the position that "Moll et al. disclose the invention as claimed except for disclosing the covering or plurality of leaflets as comprising small intestinal submucosa". For reasons similar to those set forth above in the analysis of the Bessler et al./Cox rejection, this position is not correct. Claim 55 includes the feature of "the outer edge of each one of the plurality of leaflets attached along one side element of said plurality of side elements and thereby adapted to engage the wall of the bodily passage". This feature is not taught in Moll et al., which only teaches that the "[b]lood flow stoppage elements 6, having the form of flexible hollow cones, are each supported on a substantially triangular frame section 8 of a support 10Y". Similarly, in its Figures, the Moll et al. patent lacks any illustration of this claimed feature (see in particular Figure 1). Nor is there any motivation provided within Moll et al. to modify its device to meet the claimed feature. To the contrary, Moll et al. describe their device to be functional in the fashion they desire, as shown.

Looking again to the Cox reference, there are absolutely no teachings to supplement the above-noted shortcomings of Moll et al. In fact, Cox only teaches the use of a stent in conjunction with an otherwise implanted valve, wherein the stent "could be secured within the aortic wall 250, outside of the SIS segment 200. This type of stent, if used, would contain [sic] projections which extend in an inward radial direction, toward the central axis of the aorta. These projections, which would be positioned at the midpoints between the three attachment points at the

Serial No. 09/777,091

PATENT

outlet end, would prevent any flattening of the cusp regions 222 against the interior of aortic wall 250." See Col. 24, lines 3-17. Accordingly, Cox does not teach or suggest any attachment of the valve material to the stent as claimed, and thus cannot in any way supplement the teachings of Moll et al. in a manner to render the present claims obvious.

For the above reasons, the rejection of claims 55 under 35 U.S.C. 103(a) over the combination of Moll et al. and Cox is overcome, and its withdrawal is solicited.

Claims 46 and 47 are being withdrawn from consideration. As for claim 10 and 11, the same arguments apply which are presented above for claim 55. The rejection of claims 10 and 11 as being unpatentable (35 USC 103(a)) over Moll et al. in view of Cox is overcome because the references, even if combinable, do not teach or suggest the elements of the claims. For example, neither reference discloses the claim 1 limitation of the outer leaflet edges being "attached along one side element of said plurality of side elements and thereby adapted to engage the wall of the bodily passage in said path extending at least partially longitudinally and at least partially circumferentially such that the leaflet extends along said bodily passage away from the inner edges in said second direction." Therefore, we respectfully ask that the Examiner withdraw the rejection of claims 10 and 11.

**Examiner's Point 18:**

Claims 15 and 16 stands rejected under 35 USC 103(a) based upon the assertion that it is unpatentable over U.S. Patent No. 6,287,334 (Moll et al.) in view of U.S. Patent No. 5,855,601 (Bessler et al.) This rejection is respectfully traversed, because the references, even if combinable, do not teach or suggest the elements of the claims.

Applicants again present the argument that claim 1 (from which these claims depend), requires that the leaflet edges be "attached along one side element of said plurality of side elements and thereby adapted to

Serial No. 09/777,091

PATENT

engage the wall of the bodily passage. . . ". This wall-engaging outer leaflet edge that is attached along the (frame) side elements is not taught by either the Moll or Bessler reference. Therefore, the rejection is overcome, and we request that the claims be allowed.

Allowable Subject Matter

The indications of allowable subject matter given in paragraphs 21 and 22 of the Office Action are acknowledged with appreciation. In response, claims 29 and 30 have been rewritten as new claims 58 and 59 in a fashion that overcomes the rejections under 35 U.S.C. 112 and includes all of the limitations of the base claim and any intervening claims. Favorable action on claims 58 and 59 is thus solicited. Claims 6 and 13 have not been rewritten as new claims. For the reasons discussed above in conjunction with independent claim 1 from which they depend, these claims are believed to be allowable in their present, dependent form. Favorable consideration of claims 6 and 13 as presently pending is thus also requested.

New Claims

New claims 56-61 are being added by this amendment and Applicants respectfully ask that they be allowed along with the other pending claims in this application. Claims 60 and 61 are being presented for the first time.

Summary

By this action, claim 1-2, 4-6, 10-13, 15-16, and 55-61 are now pending in the application. Claims 56-61 are being added. In order to expedite the examination and allowance of the present application, claims

Serial No. 09/777,091


PATENT

7-9, 14, 17-36, and 46-54 are being withdrawn from consideration. This action should not be interpreted as an acknowledgment of the merits of the Examiner's position regarding any of the withdrawn claims. The reexamination and reconsideration of the remaining claims of this application is respectfully requested, and it is further requested that the application be passed to issue. After the Examiner has considered this amendment, it is being requested that the Examiner please telephone Applicants' representative, Mr. Agnew, to discuss any issues remaining in the case.

Respectfully submitted,

Dusan Pavcnik  
Frederick S. Keller  
Josef Rosch  
Thomas A. Osborne  
John A. DeFord  
Brian L. Bates  
Christopher G. Dixon  
Andrew K. Hoffa  
Raymond B. Leonard II  
Joseph F. Obermiller

Date: Jan. 12, 2004

By   
Charles W. Agnew, Patent Agent  
Reg. No. 44,497  
(812) 330-1824